- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00685776
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (DEFINE)
A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The 76 week treatment period is followed by a 12 week reversibility phase which can be extended by up to another 12 weeks in order to allow participants who have completed their week 88 visit to continue in the study until the Extension study is ready to be implemented.
In the optional extension, participants will be assigned to the same treatment arm to which they were assigned in the base study. The total duration of the extension study will be up to 116 weeks; which will include a 2 year treatment period, followed by a 12 week reversal phase. A post-extension study follow-up phone call will be completed 12 weeks after discontinuation or completion of study treatment. Participants previously treated with anacetrapib or placebo will be invited in a 4:1 ratio in an optional extended reversal phase. The total duration of the extended reversal phase will be 1 year.
Participants previously treated with anacetrapib in the DEFINE study will be followed periodically for up to 4 years to determine plasma levels of anacetrapib. Participants will also be invited to participate in a sub-study consisting of one clinic visit to measure anacetrapib levels in the plasma and the subcutaneous adipose tissue.
ACRONYM: DEFINE= Determining the EFficacy and Tolerability of Cholesteryl ester transfer protein (CETP) INhibition with AnacEtrapib
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Base Study:
- Patient has Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease and is treated with a statin, with well controlled LDL-C
Extension Study:
- Patient has completed the base study including the reversibility period (i.e. 12 or to up to 24 weeks).
- Patient is on statin therapy ± lipid-modifying therapy since the end of the base study and planning to continue taking a statin throughout the study
Exclusion Criteria:
- History of heart failure, arrhythmias, heart attack, unstable angina, or stroke within 3 months prior to screening, uncontrolled blood pressure, uncontrolled high cholesterol or liver disease.
- History of mental instability, drug/alcohol abuse within the past 5 years
- Pregnant or breast-feeding
- History of cancer within the last 5 years
- HIV positive
- Donated blood products within 8 weeks
- Currently participating or have participated in a study with an investigational compound within the last 30 days
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Anacetrapib
Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
|
Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
Altri nomi:
|
Comparatore placebo: Placebo
Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.
|
Participants will receive one placebo tablet once daily for 76 weeks.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Change from baseline in Low Density Lipoprotein Cholesterol
Lasso di tempo: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Number of participants with hepatitis-related adverse experiences
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with Alanine Transaminase consecutive elevations greater than or equal to 3xULN (Upper Limit of Normal)
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with Aspartate Aminotransferase consecutive elevations greater than or equal to 3xULN
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with Creatine Phosphokinase elevations greater than or equal to 10xULN
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with Creatine Phosphokinase elevations greater than or equal 10xULN with muscle symptoms
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with sodium, chloride, or bicarbonate elevations greater than ULN
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with reduction in potassium levels less than LLN (Lower Limit of Normal)
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with myalgia
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with rhabdomyolysis
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with pre-specified adjudicated cardiovascular serious adverse events
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with death from any cause
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Number of participants with significant increase in Blood Pressure
Lasso di tempo: Through 88 weeks
|
Through 88 weeks
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Change from baseline in High Density Lipoprotein Cholesterol
Lasso di tempo: Baseline, 24 weeks, and 76 weeks
|
Baseline, 24 weeks, and 76 weeks
|
Change from baseline in non-High Density Lipoprotein Cholesterol
Lasso di tempo: Baseline, 24 weeks, and 76 weeks
|
Baseline, 24 weeks, and 76 weeks
|
Change from baseline in Apolipoprotein B
Lasso di tempo: Baseline, 24 weeks, and 76 weeks
|
Baseline, 24 weeks, and 76 weeks
|
Change from baseline in Apolipoprotein A-1
Lasso di tempo: Baseline, 24 weeks, and 76 weeks
|
Baseline, 24 weeks, and 76 weeks
|
Change from baseline in Low Density Lipoprotein Cholesterol
Lasso di tempo: Baseline, 24 weeks, and 76 weeks
|
Baseline, 24 weeks, and 76 weeks
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4.
- Gotto AM Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):543-9. doi: 10.1177/1074248414529621. Epub 2014 Apr 14.
- Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.
- Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattia cardiovascolare
- Malattie vascolari
- Arteriosclerosi
- Malattie arteriose occlusive
- Malattie cardiache
- Disfunsione dell'arteria coronaria
- Ischemia miocardica
- Malattia coronarica
- Meccanismi molecolari dell'azione farmacologica
- Antimetaboliti
- Agenti anticolesteremici
- Agenti ipolipidemizzanti
- Agenti regolatori dei lipidi
- Anacetrapib
Altri numeri di identificazione dello studio
- 0859-019
- 2007_648 (Altro identificatore: Merck Study Number)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su anacetrapib
-
Merck Sharp & Dohme LLCCompletato
-
Merck Sharp & Dohme LLCCompletato
-
Merck Sharp & Dohme LLCCompletato
-
University of OxfordMerck Sharp & Dohme LLCAttivo, non reclutanteMalattia cardiovascolare ateroscleroticaRegno Unito
-
Merck Sharp & Dohme LLCCompletato
-
Merck Sharp & Dohme LLCCompletato
-
Merck Sharp & Dohme LLCCompletato
-
Merck Sharp & Dohme LLCCompletato
-
Merck Sharp & Dohme LLCTerminatoIpercolesterolemia | Iperlipemia mista
-
Merck Sharp & Dohme LLCCompletatoIperlipoproteinemia di tipo II | Ipercolesterolemia, familiare